Ariel Ann Nelson

Dynamics of nectin-4 (N4) expression in urothelial carcinoma (UC): Across disease states.

Hiba Narvel, Yetunde Ogunsesan, Anikó Szabó, Md Sakib Ibne Salam et autres

3131 Background: Enfortumab vedotin (EV), which targets N4, has revolutionized advanced UC management. Despite high prevalence of N4 in UC, the temporal stability of N4 is poorly characterized. Conflicting reports describe both decreased and increased expression in metastatic (met) UC compared to …

us (code pays fourni par la source)

CHIMERA-DDR: A Machine Learning Framework for Classifying Heterogeneous Mismatch-Repair and Homologous-Recombination Deficiency Patterns in Prostate Cancer

Komal Sharma, Yu Wang, Shabi Haider, Vineel Bhatlapenumarthi et autres

Current DNA damage repair (DDR) biomarkers employ binary classifications that fail to capture the molecular complexity of tumors with concurrent repair deficiencies. We used genomics analysis to stratify 672 metastatic prostate cancer patients into 11 DDR subgroups, identifying 51 molecular signatures with …

us, Afrique du Sud (code pays fourni par la source)

Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma

Kathryn E. Beckermann, Neil J. Shah, Matthew T. Campbell, Naomi B. Haas et autres

BACKGROUND: Anexelokto (AXL) protein and its ligand, growth arrest specific-6 (GAS6), are important drivers of metastasis in patients with advanced clear cell renal cell carcinoma (ccRCC). Batiraxcept competitively binds GAS6 limiting interaction with AXL and thereby reduces downstream signaling. We present the …

us (code pays fourni par la source)

Case Report: Oral lichenoid mucositis in a patient with metastatic renal cell carcinoma undergoing treatment with pembrolizumab and axitinib

Andrew Wellen, Michael Pierro, Karolyn A. Wanat, Ariel Ann Nelson

Stomatitis is a relatively common adverse effect of systemic pharmacologic therapy seen in the treatment of various malignancies. When severe, stomatitis has the potential to limit a patient's ability to tolerate optimal medical therapy and to impact quality of life. There are …

us (code pays fourni par la source)

A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer, (HCRN GU18-343) ABATE study.

Deepak Kilari, Anikó Szabó, Kathryn Bylow, Ariel Ann Nelson et autres

800 Background: Atezolizumab (A) has demonstrated single agent activity as neoadjuvant therapy (NAT) for muscle invasive urothelial carcinoma (MIUC) (ABACUS trial). Cabozantinib (C) has a unique immunomodulatory profile that may foster anti-tumor immunity and has demonstrated clinical activity as monotherapy and in …

us (code pays fourni par la source)

Dose Escalated Pelvic Lymph Node Intensity Modulated Radiation Therapy (IMRT) with a Simultaneous Hypofractionated Boost to the Prostate for NCCN Very-High Risk Adenocarcinoma of the Prostate, a Prospective Phase II Clinical Trial (NCT02177292)

William A. Hall, F. Chunara, Anjishnu Banerjee, Meena Bedi et autres

us (code pays fourni par la source)

Impact of cytoreductive nephrectomy (CN) and treatment (trt) sequence on overall survival (OS) in metastatic non-clear cell renal cell cancer (nccRCC).

Ariel Ann Nelson, Anikó Szabó, Deepak Kilari

e16543 Background: nccRCC accounts for 25% of kidney cancer diagnoses and encompasses a diverse group of kidney tumors with distinct biology for which trt in the metastatic setting is evolving. The role of CN for nccRCC population in the current trt landscape …

us (code pays fourni par la source)

Homologous recombination repair (HRR) alterations may be passenger events in patients with advanced prostate cancer (PC) with high tumor mutational burden (hTMB).

Vineel Bhatlapenumarthi, Navonil De Sarkar, Anannya Patwari, Emmanuel S. Antonarakis et autres

206 Background: HRR and microsatellite instability-high (MSI-H) alterations (alt) are typically mutually exclusive in pan-cancer cohorts. However, in PC 12.8% of BRCA1 and 3.4% of BRCA2 genomic alteration(alt) (Loss of function mutation or copy loss) co-occurred with MSI-H (PMID: 35772050) but were …

us (code pays fourni par la source)

New phase 1 SURPASS trial cohort: Early-line ADP-A2M4CD8 T-cell receptor T-cell therapy plus pembrolizumab in urothelial carcinoma.

David H. Aggen, Alejandro J. Garcia, Jose M Saro Suarez, Amy Sauer et autres

TPS708 Background: ADP-A2M4CD8 T-cell receptor (TCR) T-cell therapy consists of autologous CD4+ and CD8+ T-cells genetically modified to target melanoma-associated antigen A4 (MAGE-A4) in patients (pts) with advanced cancers who are human leukocyte antigen A*02 eligible. In the late-line setting, ADP-A2M4CD8 monotherapy …

us, gb, es (code pays fourni par la source)

1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy

Neal Shah, Matthew T. Campbell, Shifeng Mao, Moshe Chaim Ornstein et autres

us (code pays fourni par la source)

Outcomes of Antineoplastic Immunotherapy at a Large Healthcare Organization: Impact of Provider, Race and Socioeconomic Status

Matthew Mirsky, Carley Mitchell, Augustine R. Hong, Shufen Cao et autres

Purpose: Disparities in cancer care delivery remain a pressing health-care crisis within the United States (US). The use of immune checkpoint inhibitors (ICIs) and their management may be a disparity generator that impacts survival. This retrospective study assessed disparities in a cohort …

us (code pays fourni par la source)

Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).

Katy Beckermann, Matthew T. Campbell, Naomi B. Haas, Moshe Chaim Ornstein et autres

4534 Background: AXL is up-regulated by hypoxia-inducible factor-1 signaling in VHL-deficient tumor cells, playing a critical role in metastasis and resistance to VEGF-targeted therapies. Batiraxcept is a recombinant fusion protein containing an extracellular region of AXL combined with the human immunoglobulin G1 …

us (code pays fourni par la source)